Article
From natural killer cells to off-the-shelf CAR-Ts, biopharma targets cancer with next-gen cell ther
Rating:
0.0
Views:
74
Likes:
1
Library:
1
Following the success of personalized CAR-T treatments like Gilead's Yescarta and Tecartus for blood cancers, several companies are working on the next generation of cell therapies to treat a range of tumor types. They include off-the-shelf CAR-Ts and therapies that boost the innate ability of natural killer (NK) cells to destroy cancer.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value